|
|
30秒注册登陆，可查看更多信息，结交更多好友，享用更多功能，轻松玩转论坛，白白手拉手欢迎您的加入！
您需要 登录 才可以下载或查看，没有账号？注册新成员
x
查到ARCUTIS的一份Form10Q表格，谈及ARQ-252（ARQ-252应该就是恒瑞的SHR0302，前段时间国内白白三期临床的那个，https://xueqiu.com/1655294479/136557443）的竞争关系时，有如下描述：For hand eczema, our primary competitors include topical therapies such as branded and generic versi** of clobetasol, such as Clobex, and generic versi** of be**ethasone dipropionate. The only other prescription product candidate we are aware of under development for the treatment of hand eczema that would compete with ARQ-252 is delgocitinib, which recently showed proof-of-concept in a Phase 2a trial and has been approved in a different formulation in Japan (Corectim).
For vitiligo, our primary competitors include topical therapies such as generic and branded versi** of calcineurin inhibitors, including Elidel, marketed by Bausch Health; branded and generic versi** of high potency steroids, including Clobex, marketed by Galderma Laboratories, LP; and other treatments including various lasers and ultraviolet light-based therapies. In addition, there are several prescription product candidates under development that could potentially be used to treat vitiligo and compete with ARQ-252, including but not limited to: topical cerdulatinib, under development by Dermavant Sciences, Inc., topical ruxolitinib, under development by Incyte Corporation, and both oral PF-06651600 and oral PF-06700841, under development by Pfizer Inc.
原文：https://investors.arcutis.com/node/6956/html
简单说，就是ARQ252治疗手部湿疹，主要竞对是丙酸氯倍他索、倍他米松。除此之外，他们知道的唯一潜在竞对是迪高替尼（当时还没上市，所以是潜在的）。
ARQ252治疗白白，主要竞对包括钙调神经磷酸酶抑制剂（如爱宁达）、甾族化合物（如Clobex，不知道是啥。。），还有其他的治疗手段包括激光、紫外光等；除此之外，还有一些正在开发的潜在竞对包括但不限于：Dermavant 的cerdulatinib（SYK/JAK抑制剂）、Incyte的鲁索替尼（JAK）、还有辉瑞的口服PF-06651600和PF-06700841([size=13.3333px]Tyk2/JAK1抑制剂）。
[size=13.3333px]
[size=13.3333px]按照以上说法，好几家公司都在研究JAK治疗白白，而且鲁索替尼貌似效果还可以。所以说JAK可能会成为有效药么？
|
|
发表于 2020-8-3 15:14:19
发表于 2020-8-3 15:17:31
楼主
